Showing 463 results
-
Media Release /- PARADIGMS data also show fingolimod-treated patients had significantly fewer new brain lesions vs. those on intramuscular interferon beta-1a injections(1)- Currently there are no disease-modifying…
-
Media Release /Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
-
Media Release /- 2018 STEP Program™ designed to support unique proposals from nonprofit organizations that serve people living with sickle cell disease- Novartis will select proposals that demonstrate innovation in…
-
Media Release /- Chronic steroid use to treat the symptoms of systemic juvenile idiopathic arthritis (SJIA) can contribute to slowed growth and delayed puberty[2],[3]- The new pivotal Phase III data also showed…
-
Media Release /-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF-- PARADIGM-HF is the largest heart…
-
Media Release /NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary…
-
Media Release /- Outcomes from PIONEER-HF 4-week open-label extension reinforce initial 8-week findings, showing Entresto® (sacubitril/valsartan) continued to deliver reductions in NT-proBNP, an established…
-
Media Release /- Decision could speed access to LCZ696 for heart failure with reduced ejection fraction patients in the US, reducing total review time from 12 to 8 months(1) - Filing is based on results from the…
-
Media Release /- 82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA)- ELIANA, the first global CAR T cell…
-
Media Release /- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1)- On all-cause mortality, LCZ696 doubled the effect…
